[ A22-109] Faricimab (visual impairment due to diabetic macular oedema) – Benefit assessment acc. to § 35a Social Code Book V
Last updated 16.01.2023
Commission awarded on 14.10.2022 by the Federal Joint Committee (G-BA).
Head and nerves
Visual impairment due to diabetic macular oedema in adults
Added benefit not proven
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.